Annweiler et al., Vitamin D supplementation prior to or during COVID-19 associated with better 3-month survival in geriatric.., The Journal of Steroid Biochemistry and Molecular Biology, doi:0.1016/j.jsbmb.2021.105958
risk of death, 64.2% lower, RR 0.36, p = 0.002, treatment 16 of 67 (23.9%), control 13 of 28 (46.4%), NNT 4.4, adjusted per study, odds ratio converted to relative risk, multiple Cox proportional hazards.
Abstract: Journal of Steroid Biochemistry and Molecular Biology 213 (2021) 105958
Contents lists available at ScienceDirect
Journal of Steroid Biochemistry and Molecular Biology
journal homepage: www.elsevier.com/locate/jsbmb
Vitamin D supplementation prior to or during COVID-19 associated with
better 3-month survival in geriatric patients: Extension phase of the
Cédric Annweiler a, b, c, d, e, *, Mélinda Beaudenon b, Romain Simon b, Mialy Guenet b,
Marie Otekpo b, Thomas Célarier f, g, h, Jennifer Gautier b, on behalf of the GERIA-COVID study
School of Medicine, Health Faculty, University of Angers, Angers, France
Department of Geriatric Medicine and Memory Clinic, Research Center on Autonomy and Longevity, University Hospital, Angers, France
UPRES EA 4638, University of Angers, Angers, France
Gérontopôle Autonomie Longévité des Pays de la Loire, France
Robarts Research Institute, Department of Medical Biophysics, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, ON, Canada
Department of Clinical Gerontology, University Hospital of Saint-Etienne, Saint-Etienne, France
Chaire Santé des Ainés, University of Jean Monnet, Saint-Etienne, France
Gérontopôle Auvergne-Rhône-Alpes, Saint-Etienne, France
A R T I C L E I N F O
A B S T R A C T
Background: The objective of this extension phase of the quasi-experimental GERIA− COVID study was to
determine whether vitamin D3 supplementation taken prior to or during COVID-19 was associated with better 3month survival in geriatric patients hospitalized for COVID-19.
Methods: Intervention group was defined as all participants supplemented with vitamin D3 prior to or during
COVID-19 (n = 67). Supplements were either bolus vitamin D3 (ie, 50,000 IU per month, or 80,000 IU or
100,000 IU or 200,000 IU every 2–3 months), or daily supplementation with 800 IU. Comparator group involved
those without vitamin D supplements (n = 28). Outcome was 3-month mortality. Covariables were age, sex,
functional abilities, history of malignancies, cardiomyopathy, undernutrition, number of acute health issues,
antibiotics use, systemic corticosteroids use, and 25(OH)D concentration.
Results: 76.1 % (n = 51) of participants survived at 3 months in Intervention group, compared to only 53.6 % (n
= 15) in Comparator group (P = 0.03). The fully-adjusted hazard ratio for 3-month mortality was HR = 0.23 [95
%CI: 0.09;0.58](P = 0.002) in Intervention group compared to Comparator group. Intervention group had also
longer survival time (log-rank P = 0.008).
Conclusions: Vitamin D3 supplementation was associated with better 3-month survival in older COVID-19
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.